The Investigation of Percutaneous Tibial Nerve Stimulation (PTNS) As a Minimally Invasive, Non-Surgical, Non-Hormonal Treatment for Overactive Bladder Symptoms

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 May 27

PMID 37240596

Authors

Connor McPhail

Robert Carey

Sidharth Nambiar

Nadia Willison

Saghi Bahadori

Pouria Aryan

Tran Nguyen

Fariba Behnia-Willison

Affiliations

Soon will be listed here.

Abstract

Background: Overactive bladder (OAB) syndrome affects 10-15% of women, severely impacting their quality of life. First-line treatments include behavioural and physical therapy, and second-line medical treatments include medications such as vaginal oestrogen, anticholinergic medications, and ß3-adrenergic agonists-with potential adverse side effects including dizziness, constipation, and delirium, particularly affecting elderly populations. Third-line treatments include more invasive measures, including intradetrusor botulinum injections or sacral nerve modulation, with percutaneous tibial nerve stimulation (PTNS) being a potential alternative treatment.

Aims: The aim of this study was to explore the long-term efficacy of PTNS treatment for OAB in an Australian cohort.

Materials And Methods: This is a prospective cohort study. Patients underwent Phase 1 treatment, whereby women received PTNS treatment once per week for 12 weeks. Following Phase 1, women entered Phase 2, whereby they received 12 PTNS treatments over 6 months. Their response to treatment was measured by obtaining data before and after each phase using ICIQ-OAB and the Australian Pelvic Floor Questionnaire (APFQ).

Results: Phase 1 included 166 women, with 51 completing Phase 2. There was a statistically significant reduction in urinary urgency (29.8%), nocturia (29.8%), incontinence (31.0%), and frequency (33.8%) compared to the baseline. Patients who completed Phase 2 also showed a statistically significant reduction in urinary frequency (56.5%).

Conclusions: Overall, the results from this study are positive and support that PTNS is a minimally invasive, non-surgical, non-hormonal, and effective treatment for OAB. These results suggest that PTNS may be a second-line treatment for patients with OAB not responding to conservative management or for patients aiming to avoid surgical approaches.

Citing Articles

Percutaneous Tibial Nerve Stimulation's Impact on Sexual Function in Female Patients with Neurogenic Detrusor Overactivity, Sexual Dysfunction, and Multiple Sclerosis.

Zachariou A, Giannakis I, Kaltsas A, Zikopoulos A, Skentou C, Stavros S J Clin Med. 2024; 13(20).

PMID: 39457993 PMC: 11508524. DOI: 10.3390/jcm13206042.

Neuromodulation guide for the non-neuromodulator clinician: What it is and how it can benefit patients?.

Hoffmann C, Wang J, Ali R, DSouza R Biomol Biomed. 2024; 25(2):304-313.

PMID: 39132949 PMC: 11734817. DOI: 10.17305/bb.2024.10967.

Posterior Tibial Nerve Stimulation for the Treatment of Detrusor Overactivity in Multiple Sclerosis Patients: A Narrative Review.

Sapouna V, Zikopoulos A, Thanopoulou S, Zachariou D, Giannakis I, Kaltsas A J Pers Med. 2024; 14(4).

PMID: 38672982 PMC: 11050849. DOI: 10.3390/jpm14040355.

References

Wang M, Jian Z, Ma Y, Jin X, Li H, Wang K . Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J. 2020; 31(12):2457-2471. DOI: 10.1007/s00192-020-04429-8. View

Tudor K, Seth J, Liechti M, Ochulor J, Gonzales G, Haslam C . Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder. Clin Auton Res. 2018; 30(1):61-67. DOI: 10.1007/s10286-018-0553-8. View

van der Pal F, van Balken M, Heesakkers J, Debruyne F, Bemelmans B . Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary?. BJU Int. 2006; 97(3):547-50. DOI: 10.1111/j.1464-410X.2006.06055.x. View

High R, Winkelman W, Panza J, Sanderson D, Yuen H, Halder G . Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?. Int Urogynecol J. 2020; 32(1):149-157. DOI: 10.1007/s00192-020-04392-4. View

Nitti V . The prevalence of urinary incontinence. Rev Urol. 2006; 3 Suppl 1:S2-6. PMC: 1476070. View

Karjalainen P, Tolppanen A, Mattsson N, Wihersaari O, Jalkanen J, Nieminen K . Pelvic organ prolapse surgery and overactive bladder symptoms-a population-based cohort (FINPOP). Int Urogynecol J. 2021; 33(1):95-105. PMC: 8739293. DOI: 10.1007/s00192-021-04920-w. View

Willis-Gray M, Dieter A, Geller E . Evaluation and management of overactive bladder: strategies for optimizing care. Res Rep Urol. 2016; 8:113-22. PMC: 4968994. DOI: 10.2147/RRU.S93636. View

Karsenty G, Denys P, Amarenco G, De Seze M, Game X, Haab F . Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2007; 53(2):275-87. DOI: 10.1016/j.eururo.2007.10.013. View

Game X, Mouracade P, Chartier-Kastler E, Viehweger E, Moog R, Amarenco G . Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol. 2009; 5(3):156-64. DOI: 10.1016/j.jpurol.2009.01.005. View

10.

Scarneciu I, Lupu S, Bratu O, Teodorescu A, Maxim L, Brinza A . Overactive bladder: A review and update. Exp Ther Med. 2021; 22(6):1444. PMC: 8549091. DOI: 10.3892/etm.2021.10879. View

11.

van Balken M . Percutaneous tibial nerve stimulation: the Urgent PC device. Expert Rev Med Devices. 2007; 4(5):693-8. DOI: 10.1586/17434440.4.5.693. View

12.

Raju R, Linder B . Evaluation and Treatment of Overactive Bladder in Women. Mayo Clin Proc. 2020; 95(2):370-377. DOI: 10.1016/j.mayocp.2019.11.024. View

13.

Wein A, Rackley R . Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol. 2006; 175(3 Pt 2):S5-10. DOI: 10.1016/S0022-5347(05)00313-7. View

14.

Mohee A, Khan A, Harris N, Eardley I . Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2012; 111(1):106-13. DOI: 10.1111/j.1464-410X.2012.11282.x. View

15.

Wein A, Rovner E . Definition and epidemiology of overactive bladder. Urology. 2002; 60(5 Suppl 1):7-12; discussion 12. DOI: 10.1016/s0090-4295(02)01784-3. View

16.

Irwin D, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C . The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009; 103(2):202-9. DOI: 10.1111/j.1464-410X.2008.08036.x. View

17.

Wyman J, Burgio K, Newman D . Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009; 63(8):1177-91. PMC: 2734927. DOI: 10.1111/j.1742-1241.2009.02078.x. View

18.

Coyne K, Margolis M, Jumadilova Z, Bavendam T, Mueller E, Rogers R . Overactive bladder and women's sexual health: what is the impact?. J Sex Med. 2007; 4(3):656-666. DOI: 10.1111/j.1743-6109.2007.00493.x. View

19.

Liedl B, Goeschen K, Sutherland S, Roovers J, Yassouridis A . Can surgical reconstruction of vaginal and ligamentous laxity cure overactive bladder symptoms in women with pelvic organ prolapse?. BJU Int. 2018; 123(3):493-510. DOI: 10.1111/bju.14453. View

20.

Burton C, Sajja A, Latthe P . Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012; 31(8):1206-16. DOI: 10.1002/nau.22251. View